Publications by authors named "Feiyi Cao"
Background: Lung cancer is the leading cause of cancer-related mortality worldwide. S-1, a fluorouracil derivative known for its efficacy and minimal adverse effects in various solid tumors, offers hope for advanced non-small cell lung cancer (NSCLC) patients. This study conducted a retrospective, single-center analysis to investigate the effectiveness and safety of S-1 monotherapy and combination therapy as second-line or subsequent treatment for advanced NSCLC.
View Article and Find Full Text PDFArticle Synopsis
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer deaths, and the fluorouracil derivative S-1 shows promise in treating advanced cases due to its efficacy and safety profile.
- A review of clinical studies indicated that S-1 can be effective both as a standalone therapy and in combination with other treatments, often yielding similar or better outcomes compared to immunotherapy with fewer side effects.
- The combination of S-1 with anti-vascular drugs and immune checkpoint inhibitors has demonstrated higher anti-tumor activity and better overall responses in patients with advanced NSCLC.
Patients with stage IIIA/IIIB squamous non-small cell lung cancer (SqCLC) are particularly challenging to treat with a poor 5-year survival rate and new treatment strategies are needed. In the present study, a retrospective, single-center study was conducted to explore the efficacy and safety of Endostar combined with chemotherapy as the neoadjuvant treatment in patients with stage IIIA/IIIB SqCLC. A total of 27 patients with locally advanced SqCLC treated with Endostar combined with chemotherapy as neoadjuvant therapy from January 1, 2017 to December 31, 2019 at the Zhejiang Cancer Hospital (Hangzhou, China) were included.
View Article and Find Full Text PDF